Legal and Medical Aspects of Diverse Gender
Identity in Childhood
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Diagnosis of gender identity dysphoria among children and young people
appears to be increasing around the developed world. For a small proportion
of children, the mismatch between their natal physical characteristics and
desired gender causes significant distress. Though there are now accepted
medical interventions that can assist in these cases, there is a lack of
congruence between clinical practice and legal regimes governing the
treatment of children and young people in this area. This article seeks to
demonstrate the difficulties that may arise by providing a detailed explanation
of medical interventions, juxtaposed with a discussion of the legalities of
children’s consent in some overseas common law jurisdictions.
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I. INTRODUCTION
Increasing numbers of children and young people around the world are being diagnosed with “gender
identity dysphoria” or choosing not to conform to traditional gender identities. Currently, referrals for
treatment of young people for conditions related to gender nonconformism are growing more rapidly
than for any other age group.1
The response to children and young people displaying gender nonconformism throws up a host of
interconnected medical and legal issues involving the appropriateness of medical interventions, children’s
capacity to consent to medical treatment, the role of concerned adults including parents and guardians,
and social and legal recognition of a person’s chosen gender. The deeply personal nature of the issues that
can arise – and which appear to be arising with ever-greater frequency among young people – demands a
sophisticated understanding of the interaction of medical and legal constructs in this area.
It is important to note that “gender dysphoria” is distinct from being of diverse, non-binary or
“nonconforming” gender identity, due to the levels of distress experienced by sufferers at the lack of
congruity between their experienced gender and their body. While there is no uniform mode of “treatment”
for gender dysphoria, as each individual’s situation is different, there are various medical levels of what
is referred to as “affirmation” of gender.2 The most dramatic is surgery to redefine the genitalia, an
irreversible and reproductively sterilizing surgery. Medical assessment before such surgery must ensure
that it is essential for the individual’s wellbeing. There are also less invasive options including hormone
therapy. These less irreversible therapies, if successful, may also work to provide individuals with a
satisfactory quality of life.
Medical advances in this area have not necessarily been matched by legal change in the common law
world. Despite many progressive changes, it seems that there remains a significant mismatch between
current medical best practice and legal regimes dealing with children and young people’s gender
expression. This article first discusses gender nonconformity and gender dysphoria in young people
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in Pt II. Part III describes various medical treatment options and what research suggests to date about
outcomes. Part IV then considers the legal issues that can arise in relation to access to medical treatment
for gender nonconforming children and young people, in various common law jurisdictions, while Pt V
provides conclusions.

Prevalence of Gender Nonconformism in Young People
A UK-based charity, the Gender Identity Research and Education Society (Gires) recently estimated the
number of people identifying as gender nonconforming.3 A survey of 1,000 people found that 1% were
gender nonconforming to some degree: 0.2% overall were likely to seek medical treatment for their
condition at some stage, while 0.03% had received such treatment already. This latter figure comprised
those having already undergone transition (0.02%) and those having a gender recognition certificate4
(0.005%) or who were likely to begin treatment during the year (0.004%). The numbers who have sought
treatment seem likely to continue growing at 20% per annum (from a low total number base) or even
faster.5 Few younger people present for treatment despite the fact that most gender variant adults report
experiencing the condition from a very early age, but as noted, referrals for this age group are increasing
exponentially.
In a 2015 review, Fernández et al identified “a higher incidence of people seeking care at younger
ages, the minimum age being 13 years”.6 Likewise, Kaltiala-Heino et al observed that the number of
attendees at two gender identity clinics for adolescents in Finland was higher than expected: “The number
of referrals to the study unit already doubled the less conservative estimates based on adult figures”.7
These authors noted that referrals to such services had increased across Europe.8 Similar increases have
been noted in Australia9 and Canada.10 There are now specialist gender identity clinics for adolescents
in many countries.11 A 2011 population-based survey in San Francisco in the United States found that
1.3% of children in grades six to eight (aged 11–13 years) self-identified as transgender.12 The World
Professional Association for Transgender Health (WPATH) reviewed 10 studies focused on individuals
presenting to specialist transgender clinics. The prevalence ranged from 1:11,900 to 1:45,000 for male to
female (MtF) individuals and 1:30,400 to 1:200,000 for female to male (FtM) individuals.13 The authors
considered these to be the minimal estimates, as the studies counted only people presenting for a specific
type of treatment.
Accurate prevalence data – the actual rate of gender dysphoria in the general population – are
lacking. Thus, there is no firm evidence that overall prevalence is changing. However, a common theme
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discussed in the above studies is that there is an increasing incidence of case recognition: ie the number
of cases diagnosed in the population, representing a proportion of the actual number of cases. Increased
case recognition may increase the recognized numbers even if there is no increase or even if the true
prevalence falls.14 Regardless, it is clear that gender nonconformity in young people is increasingly
recognised as requiring a sophisticated medical, social and policy response.

II. GENDER CONCEPTS AND GENDER DEVELOPMENT
Gender, gender identity, gender role and gender expression are personal, psychological and cultural
constructs referring to various aspects of maleness and femaleness. Gender identity is an individual’s
innate sense of being male, female or somewhere in between, while gender role is society’s expectations
of attitudes, behaviours and personality traits typically based on biologic gender. Masculinity and
femininity are the main concepts conveying these cultural associations. Gender expression refers to the
ways gender is presented to the outside world but does not necessarily correlate with gender identity of
the individual. The concept that gender is binary – male or female – has become outdated and gender
should be considered as a psychological continuum from female to male. As Otto has explained:
[E]veryone has a “gender identity” – including those who identify as cisgendered … there is a dynamic
relationship between the body and identity which gives rise to multiple possible alignments, which can
change over time, or even from moment to moment.15

Such a continuum in essence means that gender nonconformity may be tolerable for an individual or may
cause significant distress to the individual, the latter being referred to as gender dysphoria. The degree
may fluctuate so the individual may be gender nonconforming or experience gender dysphoria at other
times.
A summary of gender development is important in the understanding of both nonconforming gender
identity and the continuum concept. The timing of gender identity stability is important when considering
any therapy but acutely so when considering irreversible hormonal or surgical therapies. Forcier et al
present a summary of the early development of gender.16 They report that:
Between 2 to 4 years children begin to understand gender differences, use gendered pronouns such as
“him” and “her” correctly and can identify their own gender. By this age most children also play with
toys and games that correlate with their anatomical sex.… By five to six years of age, their view of gender
becomes constant. Young children assume gender stereotypes for themselves.17

The authors go on to describe a peer group that “generally continue to be same-sex; following rules and
fitting in”.18 Although this is the usual developmental path, many children experiment with different gender
roles. Typically, adolescents’ uncertainty about their sexual orientation, eg decreases with age, from 26%
of 12-year olds to 5% of 17-year olds.19 Within the continuum of gender expression, many individuals
may find, with or without medical help, a gender role that is nondistressing (nondysphoric) associated
with a satisfactory lifestyle. For reasons that are not understood, however, in some children “cross gender
behaviour and expression is more consistent, persistent and insistent than it is in their peers”.20 These
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children or adolescents may well suffer intolerable gender dysphoria and require affirmation of their
gender identity in some form.
The concept of a continuum of gender is anathema to legal constructs of gender.21 Typically, legal
regimes regulating birth and identity require a child’s gender to be determined and fixed at birth and
reflected in the issuance of a birth certificate. Trans*, intersex and nonidentifying people may face many
barriers in seeking legal recognition of their identity.22
In many countries, it is now possible to change one’s legal status as male or female, through (for
example) obtaining a “gender recognition certificate” or amending one’s birth certificate. However, there
is inconsistency in the prerequisites for doing so, namely, the degree of affirmation of gender identity –
which may range from presenting or living as that gender to undergoing surgical procedures.23 In many
parts of the world, legal recognition will only follow if the most extreme forms of physical change have
been pursued. The organisation Transgender Europe has collated information about Europe’s different
legal regimes and how they recognise gender.24 While some jurisdictions, such as Malta Portugal and
Argentina, have adopted statutes by which gender recognition is largely about the individual’s subjective
identity,25 others, such as Belgium, France and the Czech Republic, accord recognition only if gender
affirmation surgery has been performed.26 The use of a “medical model” in determining a person’s
entitlement to legal recognition of their gender identity has been extensively criticised.27
Additionally, young people are not always able to make use of the provisions of gender recognition
statutes. For example, Ireland, which has also seen growing awareness of gender nonconformity in
children,28 enacted a Gender Recognition Act in 2015 enabling people to apply for a legal change of
gender. This legislation has, however, been criticised for omitting children and young people from its
scope,29 which is also the case for the United Kingdom’s equivalent legislation.30 Thus, a person must be
18 in order to have their legal gender changed, though 16- and 17-year olds can seek to do so through the
courts. Children aged under 16 years cannot change their legal gender.31
Finally, it must be noted that regimes providing for a “change” in legal gender still deal primarily
in the male/female binary. Tran and Glazer have identified that, at least in the United States,
discrimination and other legal claims are easier to sustain when a person is seeking recognition of a
such a “change”, whether MtF or FtM.32 In contrast, those whose gender identity is less dualistic face
21
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increased difficulties.33 Australia’s highest court has recognised that a person may be legally identified
as being of “non-specific” gender.34 With a few exceptions, however, the recognition legislation of
other jurisdictions has little to offer non-binary, genderqueer and nongendered people.

III. MEDICAL TREATMENT OPTIONS AND OUTCOMES
Since the last third of the previous century, the treatment of gender dysphoria has involved hormonal
delay of puberty, sex hormone therapy and surgery to affirm the gender of dysphoric patients. These
three “stages” are described in detail below, followed by an analysis of the current research surrounding
patient satisfaction with medical transition. Social concerns surrounding, in particular, irreversible
physical effects including sterilization in young people mean that longer-term satisfaction is very
important. However, while minimal irreversibility appears to be a sound therapy, this must not come at
the detriment of the individual. Generally, satisfaction rates are high and have been quoted as 87% for
MtF patients and 97% for FtM patients.35 Dissatisfaction rates are reportedly correspondingly low: MtF
1–1.5%, FtM less than 1%.36 Nevertheless, the irreversibility of surgery, and to some extent hormonal
therapy, indicates that the clinician(s) involved must be cautious in every case. Thus, the development of
standardized assessment and therapy regimes and multidisciplinary clinics has occurred in many parts of
the world. As in all areas of medicine, treatment needs to be effective and safe.

Suppression of Puberty and Application to Gender Nonconforming
Children
Much of the medical knowledge of how to suppress puberty comes from the medical treatment of what is
called normal development precocious puberty (also known as central precocious puberty, gonadotropindependent precocious puberty or true precocious puberty). Normal development precocious puberty is
the onset of pubertal development before the age of eight years in girls and nine years in boys.
The hypothalamic–pituitary–gonadal (HPG) axis is the controlling physiological system for pubertal
development. The HPG axis is biologically active in utero and briefly during the first week of life. The
axis then becomes more active again during infancy, with peak activity between one and three months of
age. This state yields sex steroid levels comparable with those seen in early-to-mid puberty, but without
peripheral effects because the target organs are insensitive. In boys, gonadotropin concentrations then
decrease to prepubertal levels by six to nine months of age. In girls, luteinizing hormone (LH) levels
decrease at the same time as in boys, but the follicle-stimulating hormone (FSH) concentrations can
remain elevated into the second year of life.37
At the time of puberty, the HPG axis matures and the released sex hormones then do affect the
peripheral organs (due to the development of organ hormone receptors) with the development of secondary
sexual characteristics correlating to the child’s biogenetic sex. The typical stages of development were
described by Tanner and Marshall in 196938 and 197039 and are therefore known as Tanner stages 1
through 4. In most populations, attainment of pubertal milestones approximates a normal distribution,
with a mean age of onset of puberty of about 10.5 years in girls and 11.5 years in boys and a standard
deviation of approximately one year.
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Normal development precocious puberty is caused by early maturation of the HPG axis. It is
characterized by sequential maturation of breasts and pubic hair in girls and maturation of the testes,
penis and pubic hair in boys, with sexual characteristics corresponding to the child’s biogenetic sex.40
Delay of normal development precocious puberty is achieved by using gonadotrophin-releasing hormone
(GnRH) agonist or an antagonist. GnRH agonists and antagonists exhibit different mechanisms of
action. Agonists bind to GnRH receptors and produce an initial intense stimulation. This causes marked
increases in LH, FSH and testosterone. Sustained pituitary overstimulation will eventually downregulate
or desensitize GnRH receptors with a consequent decrease in hormone levels. In contrast, antagonists
block receptors, immediately stopping LH secretion, and thus producing rapid testosterone suppression
without the initial LH and testosterone surge. Once treatment is ceased, normal pubertal development
recommences and occurs within one year.41
This treatment has been found to be safe and effective in delaying normal development precocious
puberty. Treatment with GnRH agonists appears to have no significant long-term effects on the pituitary–
gonadal axis. In long-term follow-up of girls who were treated with GnRH agonists, the rate of regular
menstrual cycles and fertility was not different from the general population. For boys, small studies show
normal gonadal function after completing treatment with GnRH agonists. Although earlier pubertal
development is associated with obesity, long-term treatment with GnRH agonists does not appear to
cause or exacerbate obesity in adolescence or adulthood. While bone mineral density may slightly
decrease during GnRH agonist administration, these changes are not sustained, with preservation of
peak bone mass accrual after discontinuation of therapy.42
The application of puberty-suppressing therapy to gender nonconforming children is used for
reasons that differ from use in normal development precocious puberty. The goal of therapy is to allow
adolescents more time to explore their gender nonconformity. Subsequent transition or affirmation of
gender identity may be made easier by preventing the development of secondary sexual characteristics43
and also by averting negative social and emotional consequences of gender dysphoria.44
The therapy is started when puberty reaches Tanner stage 2 (of 4).45 Importantly, earlier therapy
is not recommended as gender nonconforming prepubescent children have a significant rate of losing
gender dysphoria with ageing.46 Meanwhile, evidence suggests that patients with continued gender
dysphoria at the onset of puberty do not change their minds.47
As in the treatment of precocious puberty the therapy has proven to be safe and reversible, having
been used now for over 20 years.48 Delay of puberty is recommended to continue until the age of 16
years when sex hormones are added to initiate pubertal development of the desired sex.49 Further delay
can lead to similar emotional concerns that have been associated with constitutional delay of puberty.
Thus, some researchers advocate using the age of 16 years as a guideline while considering the earlier
initiation of cross-gender hormones on a case-by-case basis. Earlier initiation would only come after
40
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careful review of the potential risks and benefits with the young person and parents or guardians.50
Continuation of pubertal suppression is recommended until gender affirmation surgery that includes
gonadectomy (surgical removal of the gonads) is performed.51 Surgical removal of the gonads removes
the major natal sex hormone-producing glands and thus continuation of pubertal suppression becomes
unnecessary.
Puberty can also be halted in adolescents who are in later stages of puberty. However, physical sex
characteristics such as breast development in girls and lowering of the voice and outgrowth of the jaw
and brow in boys cannot be completely reversed. Further, while hormones started during adolescence
can decrease full development of the genitals, only surgery can change the appearance of the genitals to
the desired gender.

Use of Feminising and Masculinising (Sex) Hormonal Therapy, Effects
and Side Effects
An important overarching point is that the use of hormonal therapy limits fertility. Therefore, all
patients should be informed about the prospects for reproduction and the methods available for allowing
reproduction. These methods include sperm preservation and oocyte (egg) or embryo freezing.52
Tangprica et al list the goals of hormonal therapy as being to both suppress the hormones of the
individual’s biogenetic gender and induce secondary sex characteristics of the new, desired sex. After
achieving these goals, the aim is to maintain the hormones in the normal physiological range for the
desired sex. The therapy is continued even after surgical sex affirmation. Hormone doses in excess of
the normal physiological requirements are unnecessary and harmful.53 The following sections briefly
describe the “ideal” treatment for both MtF and FtM patients who commence transition in adolescence
with sex hormone therapy.54
Feminizing Hormone Therapy for Male to Female Transition in Adolescence
The development of hormone therapy for male to female (MtF) transition (transgender female) has
not occurred via controlled trials. Rather, the accepted regime follows that developed as treatment for
hypogonadism, a condition where the normal development of sex hormone surge at puberty does not
occur. The nature of the treatment means that MtF patients require antiandrogen (testosterone) therapy
as well as feminizing hormones. Antiandrogens such as GnRH agonists (though these are typically
expensive) or spironolactone (an inexpensive blood pressure-lowering agent with an excellent safety
profile) are used.
Ideally, the patient’s treatment starts early enough to bypass the development of male secondary
sexual characteristics associated with puberty, allowing the individual to progress through puberty on a
female trajectory. If a patient begins treatment after puberty is complete, or near-complete, administration
of estradiol and androgen blockers will not affect voice pitch, laryngeal prominence, height, foot and
hand size, or facial hair growth.
Oestrogen causes breast tissue growth whenever the hormone is administered and the effect is
irreversible. The maximum growth occurs after two years of commencing administration. Thus, cosmetic
surgery of the breast should be delayed until the breast tissue is in a stable situation. Other oestrogen
effects include a change in body fat composition with increased subcutaneous fat and decreased lean
body mass. There is a decrease in facial and body hair. These changes regress if oestrogen therapy is
ceased. The skin has decreased sebaceous gland activity resulting in dry skin and nails.
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Adverse effects include development of deep venous thrombophlebitis (though this appears related
to the use of oral ethinyl estradiol, rather than other oestrogens). Oestrogens are associated with the
development of prolactinoma (a prolactin-secreting tumour of the pituitary gland), hypertension, liver
disease, decreased libido and increased risk of breast cancer. Androgen blockers can cause hyperkalemia
and decreased blood pressure. Most transgender females receiving cross-gender hormones will experience
a decrease in testicular mass, penis size and fertility, which is irreversible and slowly developing.
Masculinising Hormone Therapy for FtM Transition in Adolescence
In patients transitioning from FtM (transgender male), ideal treatment would again start early enough
to bypass the development of female secondary sexual characteristics; however, some guidelines
recommend starting GnRH analogues later, at Tanner stage 2 or 3.55 Some natal females may have started
menses, and most will have started breast tissue development by this time. The use of GnRH analogues
may lead to the regression (disappearance) of the early stages of puberty (sequential maturation of
breasts and pubic hair development), but large-scale studies are needed before definitive statements can
be made about this aspect of treatment.
The administration of testosterone in transgender male patients will induce a drop in the voice
and irreversible clitoral enlargement and reversible facial and body hair growth, cessation of menses,
redistribution of fat and increase in lean muscle mass. Potential adverse effects include hyperlipidemia
(an increase in the triglycerides or fat levels in the blood), which is associated with premature
atherosclerosis (arterial disease); polycythaemia or increase in the red blood cell mass, which is
associated with induced cerebral infarction (stroke); male pattern baldness (if a genetic predisposition
exists); acne; and infertility.

Surgery as the Final Stage of Gender Affirmation
Gender affirmation surgery refers to the removal of the gonads and genital cosmetic surgery. For some
individuals, this is the final step to live in their preferred gender role. Gender diverse people may choose
not to take this step, however. Formerly, in many countries, so-called sex reassignment surgery was
required before a person’s legal identity could be amended. As noted above, while many jurisdictions
still retain such laws, others have amended their legislation so that a person’s self-identification and
living as their preferred gender is sufficient.
Cosmetic results of genital surgery have improved since the first operations were performed in
Germany in the 1930s. An American, Christine Jørgensen, is perhaps the most famous recipient of
gender affirmation surgery, having her surgery done in Denmark in late 1952.56 With the current surgery,
neurological sensation is now preserved, resulting in better patient satisfaction with sexual function. In
all cases, genital surgery is complex and specialized, and accordingly best performed by an experienced
team.
MtF Surgery
The goal of MtF surgery is to create a “neo-vagina”. Bilateral orchiectomy (removal of the testicles) is
performed to remove endogenous testosterone production. This is followed by penectomy (removal of
the penis) and surgery to create a clitoris and a vagina (using penile skin for vaginal lining and scrotal
skin for the creating labia). Postoperatively, vaginal dilators are used on a regular basis to maintain the
vaginal length until successful and consistent sexual intercourse has been established.
As breast development maximises after two years of hormonal (oestrogen) therapy, breast
augmentation is delayed until final growth is attained. A decision for or against breast augmentation can
then be made. Cosmetic facial surgery may also be performed to create more feminine features.
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FtM Surgery
Major surgery involving oophorectomy, hysterectomy and vaginectomy is performed after several
years of androgen therapy. One option is creation of a neo-penis or neo-phallus, but the surgery is
complex and requires multiple stages. Free flaps removed from arms or legs are used to construct a
neo-phallus.57 Metoidioplasty,58 the alternative, is a procedure where the clitoral hood is lifted and
the suspensory ligament of the clitoris detached from the pubic bone, allowing the clitoris to extend
further. When the female tissues have been primed with testosterone, the clitoral head may resemble an
adolescent glans penis, although the proportionality or size may be smaller. The urethra is lengthened
using an anterior vaginal wall flap to reach the tip of the phallic glans. A scrotum can be constructed
from the labia majora, and testicular prostheses can be implanted. This surgical intervention allows
the patient to urinate standing. A penile prosthesis confers the ability for sexual penetration. Breast
size does not decrease significantly with androgen therapy, and breast glandular tissue remains.
Thus, another common surgical procedure is mastectomy. These procedures are typically performed
within two to three years of initiating testosterone therapy. The surgery is complex, and there may be
significant complications.

Prediction of Outcome and Eventual Outcome
Given the irreversibility of gender affirmation surgery, and to a lesser degree of cross-sex hormone
administration, it would be desirable to have insight into factors that predict success or failure. Prospective
controlled studies specifically designed to assess outcome and its prognostic factors are difficult with
this relatively rare condition and are still lacking, though research is ongoing. In March 2016, the journal
Nature reported on a United States National Institute of Health study, which will be both the largest
ever study of transgender young people and only the second study to track the psychological effects of
delaying puberty and its medical implications.59
Gender affirmation surgery does appear to improve gender dysphoria and psychological functioning
in most individuals.60 There are estimates that 1–2% will have regrets61 although media representations,
including internet forums, may suggest a different but unproven estimation. People who have experienced
gender dysphoria late in adult life, without strong manifestations in childhood, and others who have
difficulty in transitioning to the new sex because of their appearance or limited social skills are reportedly
over-represented among those dissatisfied.62
Gender affirmation surgery that includes hormonal therapies results in significant improvements
in quality of life and psychosocial outcomes. This was illustrated in a meta-analysis of 28 studies
that enrolled 1,833 individuals with gender identity dysphoria (1,093 MtF and 801 FtM) who
underwent gender affirmation surgery that included hormonal therapy.63 The importance of a
transitioning period to the desired gender relatively early in life and with significant psychosocial
support appears essential. This pooled analysis showed that patients improved in relation to their
gender dysphoria (80%), psychological symptoms (78%), quality of life (80%), and sexual function
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(72%). Little attention has been paid to the sexual function aspect, and research has been based on
self-report. There appears to be a correlation between sexual function and the quality of the neovagina or neo-phallus.64 While not all postoperative trans* people are orgasmic, many report sexual
satisfaction.65
A large prospective study from the Netherlands showed that fewer than 2% of patients undergoing
gender affirmation surgery expressed regret.66 Although unproven, these studies suggest that early
transition starting at puberty provides adolescents with the best medical outcome.

IV. LEGAL ISSUES ARISING IN THE TREATMENT OF CHILDREN AND YOUNG PEOPLE
OF NONCONFORMING GENDER IDENTITY
The legal situation for children and young people of nonconforming gender identity can be complex. As
detailed above, there are various treatment options, with hormone therapy the most typical for children
and adolescents, though adolescents may also seek surgery before the age of legal adulthood, which
is typically 18 years. As explained, it is likely that the best physical and psychological outcomes for
many gender dysphoric young people will be achieved by suppressing puberty. Thus, in many instances,
treatment would ideally begin prior to reaching legal adulthood or even before the age of 16 years, an
age at which young people are (in many jurisdictions) often presumed competent to consent to medical
treatment. There is, accordingly, a mismatch between medical best practice and legal requirements
around consent. Others have noted that the law on young people’s consent to medical treatment is
already “confusing and incoherent” for health workers.67 The mismatch between clinical best practice
and legal strictures may be bewildering and frustrating for families and doctors who wish their child
or patient to receive the best possible care.68 On the other hand, there is social concern about invasive
treatment options which may have far-reaching consequences, being applied to young people who are
not themselves considered capable of providing informed consent – especially as the condition may not
persist.
It should be noted that often young people of diverse gender identity face a range of hurdles
in their everyday life. In particular, bullying and harassment, absence of family acceptance and
social stigma are important issues that have been the subject of campaigning.69 Schools have been a
particular focus, and in many jurisdictions, laws and policies are changing to foster more inclusive
treatment of diverse gender identities.70 This article’s focus is, however, on young people’s ability
to access medical treatment, particularly in the absence of support or agreement from parents or
guardians.
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Young People’s Access to Medical Treatment
In common law jurisdictions, access to any kind of medical treatment is an issue primarily revolving
around informed consent. Without this, medical treatment may constitute trespass to the person, assault
or battery.71 Consent is both legally and ethically essential as a precursor to any kind of invasive medical
treatment. A person must understand the implications, pros and cons of receiving or not receiving
treatment in order to be deemed capable of making the decision to agree. Thus, if children are found
to be “competent” to consent to treatment, they may do so themselves. If not, parents or guardians can
typically authorise treatment for the child.
Bridgeman has noted that this focus on free agreement and individual autonomy is the hallmark
of liberal individualism.72 Young children, she suggests, “[confound] this understanding of the self”
due to their dependency on others to care for them.73 Historically, children were thought to lack the
ability to make various decisions for themselves, including about medical treatment. Fernández et
al explain that the early versions of the WPATH Standards of Care74 presumed that only adults could
seek treatment, due to the requirement for informed consent.75 Yet, views about young people’s
capacity to provide such consent have changed over time, so while a young person may still be
deemed to lack capacity to make a certain decision, there is no blanket assumption that this is the
case. The most recent version of the WPATH Standards thus explains that treatment can occur
where:
The adolescent has given informed consent and, especially when the adolescent has not reached the age
for giving such consent, the parents or other guardians have consented to treatment and are involved in
supporting the adolescent during treatment.76

Often, young people are able to give informed consent. In situations where this is not the case, a parent
or guardian is usually able to agree to the treatment on the young person’s behalf. Thus, if recommended
by medical professionals and supportive of the child accessing or commencing treatment, in many
jurisdictions, this will be sufficient. Australia differs from other common law countries in this regard by
requiring (at the time of writing) court approval to be obtained before a minor may commence feminizing
or masculinising hormone therapy.77 Of course, aside from the legal regime, practical problems still
arise in accessing treatment for gender dysphoria, including a lack of specialised clinics and medical
professionals, and healthcare costs.78
If a young person’s parents or guardians are not supportive of his or her gender identity or treatment
or if only one is supportive, the legal situation becomes more complex. Young people may be reluctant to
disclose feelings about gender and sexuality to their family: Hoshall has noted that “[m]any children and
teens who identify as LGBTQ are not open with their parents about their orientation or identity”.79 Shield
cites one study of young people using a gender identity clinic, which “found that over half reported
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relationship difficulties with their parent or guardian”.80 Thus, a young person may only wish to access
treatment privately, without his or her family’s knowledge.
The options for the young person are then varied. An adolescent may be unable to access any treatment
until he or she reaches the age of majority when parental consent is typically no longer required.81
Alternatively, there are various options for young people to access treatment in the absence of parental
consent, including seeking consent elsewhere or demonstrating sufficient maturity to be permitted to do so.
As a last resort, young people may also turn to unregulated methods of obtaining hormones.
The following sections consider some issues which may arise involving: children’s ability to consent
to different treatment options whether children are able to access medical advice and treatment without
the consent of a parent or legal guardian and when two parents or guardians are in conflict over the best
treatment for a child or young person.
The Capacity of Children and Young People to Consent
Generally, a young person’s capacity to consent to receiving medical treatment is acknowledged to
vary with individual circumstances. Hence, those below the age of legal majority can often still consent
to medical treatment. Cave reports that while some jurisdictions, such as Bulgaria, “insist” on legal
adulthood as a precursor to consent, others prescribe younger ages: she quotes 15 in Denmark and
Slovenia; 16 in Spain.82
In England and Wales,83 the seminal House of Lords decision Gillick v Wisbech Area Health
Authority84 determined that whether a child or young person is competent to consent to medical treatment
depends upon the comprehension and maturity of the individual child. Gillick enshrined the position
that it is possible for children to consent to their own health care if they are of “sufficient maturity
and intelligence to understand the nature and implications of the proposed treatment”.85 Although
this would apply to any child under 18, the legal age of majority, the Family Law Reform Act 1969
extends this by presuming that a person of 16 years and above is able to consent to “surgical, medical
or dental treatment”.86 Similar statutes, setting a presumptive age of consent to medical treatment, exist
in many jurisdictions, for example, Ireland,87 Scotland,88 New Zealand,89 some states of Australia90 and
Denmark.91 Australia has also adopted the test from Gillick,92 as has Canada93 which recognises a similar
doctrine of the “mature minor”.94 This doctrine says that young people who are not yet legal adults may
S Shield, “The Doctor Won’t See You Now: Rights of Transgender Adolescents to Sex Reassignment Treatment” (2007) 7
Dukeminier Awards Best Sexual Orientation & Gender Law Review 99, 110; citing D Di Ceglie et al, “Children and Adolescents
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nevertheless consent to medical treatment if they are able to understand the nature of the treatment,
alternatives to it, and consequences.95
In the United States, people under the age of 18 years typically cannot consent to medical treatment,
and therefore the consent of a guardian is required though this varies greatly by State.96 Coleman
and Rosoff have explained that there is no uniform rule regarding exceptions to the requirement for
parental or guardian consent though many States do have such exceptions.97 For example, a young
person can be “emancipated”, married or enlisted in the armed forces at the age of 16 years and
thereafter make his or her own decisions about medical treatment.98 However, Coleman and Rosoff
reported in 2013 that 33 States and the District of Columbia had no other exceptions; in other words,
no exceptions related to the young person’s capacity or maturity.99 Of the remaining 17 States, they
explain that:
14 … permit mature minors to consent to general medical treatment either in all or a range of restricted
circumstances, and 3 states allow minors regardless of their age or maturity to consent to treatment in
either all or limited circumstances.100

Coleman and Rosoff emphasise however that there is no consistent doctrine regarding “mature minors”
in the United States.
The Right to Refuse Medical Treatment
In a number of common law jurisdictions, a young person’s right to refuse medical treatment has been
(and arguably continues to be) perceived as a more pressing and divisive issue than the right to access
it.101 Many of the key cases involving parental or guardian refusal of consent are those where the young
person has also refused treatment. This has occurred where young people or their families hold religious
beliefs which prohibit certain treatment, such as blood transfusion; where families prefer alternative
therapies; or where the child and family determine that the pain and suffering that would be caused to
the child by the proposed treatment outweigh its potential benefits.102
Though courts have been willing to find children are able to consent to medical treatment, they have
often baulked at finding that children may refuse treatment, particularly if refusal will have serious or
life-threatening consequences.103 A minor’s refusal of treatment is considered differently in law, as was
explained in the English case of Re R (A Minor) (Wardship: Medical Treatment),104 a decision of the
House of Lords:
[W]here a young person objects [to receiving treatment], even where that young person is Gillick competent
or where that person is entitled to consent under section 8 of the Family Law Reform Act 1969, they do not
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thereby acquire a right to refuse consent; a refusal of consent, unless statute otherwise indicates, always
raises the issue of welfare.105

The child’s refusal may be overridden by the court’s obligation to act in the child’s best interests.106 This
is in contrast to a competent adult’s right to decline treatment regardless of the severity of consequence.107
Cave suggests that the position is arguably different in Scotland, where the enabling statute would allow
16- and 17-year olds to refuse consent as well as give it.108
In Canada, the issue of whether a “mature minor” could refuse life-saving treatment arose in AC v
Manitoba (Director of Child and Family Services),109 a case involving a 14-year old. The first instance
judge found that although AC was competent, her decision to refuse a blood transfusion was subsumed to
the court’s statutory power to act in the best interests of a child under the age of 16 years.110 Ultimately,
the Supreme Court of Canada found that this statute was constitutional.111 Similar cases have arisen
in the United States involving adolescents’ rejection of blood transfusions, where the court has not
permitted refusal.112

Disputes Over Young People’s Access to Medical Treatment
Young people’s rights to access medical treatment in the face of opposition, or lack of support, from
parents or guardians or even without their parents or guardian’s knowledge, have arisen in cases involving
adolescents’ access to contraception and abortion. As noted, in many jurisdictions, a person under the
age of 16 years cannot access treatment without parental consent but there are various exceptions. In
an emergency situation, treatment may be administered regardless. Court orders may also be sought to
enable treatment without parental or guardian consent.113
If a young person’s parents or guardians do not support a course of treatment, and the child is
not able to consent, the courts can be called upon to decide whether the family’s opposition should be
overridden. Cases have dealt with instances where the child’s life is at risk, including through needing
a blood transfusion,114 having cancer115 and being HIV positive.116 In these cases, children have tended
to be either too young to express an opinion, being babies or infants;117 or be in agreement with their
parents’ rejection of treatment.
The failure or refusal of parents or a guardian to consent to appropriate medical treatment for a child
may also constitute neglect – grounds for taking the child into the care of the State or monitoring how
the child is being cared for within the family.118 This is the case, eg in England and Wales,119 Ireland,120
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Canada,121 Australia122 and the United States.123 This type of state intervention has occurred in some
of the “refusal” cases described above. For example, in AC v Manitoba (Director of Child and Family
Services), child welfare authorities “apprehended” AC and applied for a court order requiring the blood
transfusion to be administered.124
The medical treatment of gender nonconforming children and young people differs in key respects
from the existing debate around parental refusal of treatment for their child, however. First, although
strongly worded arguments are made to suggest that the denial of treatment for gender identity issues
can be life-threatening (attested to by the tragically high rate of suicide by gender nonconforming young
people),125 this is harder to ascertain in individual cases than, eg the prognosis for cancer or immediate
need for a blood transfusion. Given the length of time that treatment potentially spans, emergency
exceptions are also highly unlikely to apply.
Second, family support is generally a very important aspect of clinical decision-making concerning
treatment for gender identity issues. As noted, while accepting that young people may consent to
treatment, the WPATH Standards also emphasise the importance of family support, stating that “[m]ental
health professionals should help families to have an accepting and nurturing response to the concerns of
their gender dysphoric child or adolescent. Families play an important role in the psychological health
and well-being of youth”.126 Thus, proceeding with treatment when a young person lacks emotional and
social supports may lead to complications and difficulties.
Third, children will not be babies or infants. No form of hormone therapy is appropriate until the
onset of puberty, which as noted is typically around 10 or 11 years. Thus, although the court’s “welfare”
impetus will remain the same, the views of the child or young person in question must inevitably be
considered.
A further issue will arise if parents or guardians cannot agree with one another as to whether a
young person should be permitted to undergo treatment. In the jurisdictions discussed above, this would
generally be treated by the courts as a family law issue concerning an aspect of parental responsibility.
Typically, the concept of “custody” or “residence” of a child includes the responsibility for making
medical decisions for the child. Thus, disputes over medical care may be treated as an aspect of parental
responsibility to be dealt with through family law processes. In England and Wales, and Scotland, eg this
could occur by seeking a specific issues order in relation to treatment.127
In instances where those with parental responsibility do not agree with one another, it may be that
the court must make a determination about whether a child may or may not access either hormonal
suppression of puberty, feminizing or masculinising hormonal therapy, or even surgical procedures. If
parties retain competing experts on the topic, this will make the court’s decision all the more difficult.
The following sections consider the issues of young people accessing medical treatment without the
knowledge of, or consent of, their families or guardians and where family law disputes have involved
disagreement over appropriate treatment for a young person.
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England and Wales
The Gillick case itself involved a minor’s confidential access to contraception.128 Mrs Gillick sought
assurances from the local health authority that her daughters would not be provided with confidential
medical advice and contraception while they were under 16. The health authority refused to provide
such assurances. Mrs Gillick’s claim was rejected by the House of Lords, holding that a girl under
the age of 16 years could be able to consent to the medical examination and treatment. Twenty years
later, in R (Axon) v Secretary of State for Health,129 another mother, Ms Axon, also unsuccessfully
challenged her children’s rights to confidential medical consultation.130 It was held in Axon that
a medical practitioner’s duty of confidentiality to a young person who is Gillick-competent is
unqualified. Moreover, the court held that Art 8 of the European Convention on Human Rights,
which protects the right to privacy and family life, does not confer a right upon parents to be
notified about their child’s seeking medical treatment once the child is able to make his or her own
decisions. Silber J explained:
As a matter of principle it is difficult to see why a parent should still retain an Article 8 right to parental
authority relating to a medical decision where the young person concerned understands the advice
provided by the medical professionals and its implications.131

Cave explains that the “extinguishment” of parental rights upon the young person attaining the
competence to make the medical decision constitutes the controversial part of Silber J’s judgment.132
What Gillick and Axon do not explain, however, is what will occur if the medical professional
considers that the child is not competent to consent to the treatment but nevertheless, in the view of
the medical practitioner, requires treatment; and how this interacts with the child’s rights (if any) to
confidentiality. Cave points out that the assessment of whether a child can consent to disclosure (and
hence a desire for confidentiality should be respected) differs from the assessment of the child’s ability
to consent to treatment.133 Thus, a young person may not be able to consent to receiving treatment
but nevertheless insist that the fact of the medical consultation itself not be disclosed to a parent or
guardian. On the other hand, the more necessary the treatment, the more justifiable may be the medical
professional’s breach of confidentiality by informing a parent or guardian.134
If a child or young person’s parents or guardians do not support the child receiving medical
treatment, the hospital or medical professional may seek an order permitting the treatment to go ahead
regardless. In England and Wales, such an order may be sought under the court’s inherent jurisdiction
to make orders for the welfare of children and others unable to care for themselves, the parens patriae
jurisdiction. Alternatively, as recently explained by the High Court,135 a “specific issues” order pursuant
to s 8 of the Children Act 1989 (UK) may be sought, as the decision involves an aspect of parental
responsibility for a child.136
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In the specific context of gender identity, this type of disagreement over medical treatment arose
in an English case, PD v SD.137 PD, aged 16 years and a natal female, identified as male. PD’s adoptive
parents, however, found PD’s gender identity difficult to accept.138 As a result, PD “at 16 years of age …
decided to disengage completely from family life with them”139 and was placed with foster carers. The
judgment concerned PD’s application to prevent his parents from receiving any information about his
treatment, life or welfare. This application was acceded to Keehan J relied on Axon, finding that PD’s
competence to consent to medical treatment effectively squeezed out the parents’ authority regarding
medical decisions.
PD was presumed to be competent to consent to medical treatment, being 16 years old. A much
more difficult issue might arise if a younger child, eg a 12-year old, wished to access hormone therapy
for the purpose of delaying puberty. As Fortin has noted, the Gillick test puts considerable power in the
hands of medical professionals, who “must decide not only whether treatment is medically indicated,
but also whether [the] patient is competent to consent to the procedure”.140 However, she goes on to note
that in all likelihood, for any treatment lying somewhere between “trivial” and “life-saving”, medical
professionals will tread cautiously in the absence of parental knowledge or consent.141
It is possible that parental failure to consent to a child undergoing hormone therapy for gender
dysphoria could be “life-threatening”. Certainly there are many reports suggesting increased risk of
self-harm and suicide for children of diverse gender identity.142 For such a dispute to reach the courts,
however, the clinic or treatment facility would need to commence court proceedings against a child’s
parents. In reality, a more likely outcome is perhaps what occurred in PD v SD, where PD’s disagreement
with his parents was so fundamental that it lead to his departing their care.143 This occurred after PD
was admitted to hospital following an overdose and subsequently spent time in a residential treatment
facility.
Canada
The Supreme Court of British Columbia recently dealt with an interlocutory issue in a case where
appropriate treatment for an 11-year-old child diagnosed with gender identity dysphoria was the subject
of dispute between the child’s separated parents.144 In K(N) v H(A), the child (referred to as JK) was
born female but expressed a strong desire to be male. Following medical consultation with various
specialists, including a psychologist and an endocrinologist, JK had commenced suppression of puberty
with hormone therapy and had been administered two injections (to be administered on an ongoing,
monthly basis) of Lupron.145 JK had also commenced social transition at school.
JK’s father sought to restrain administration of hormones to JK and for counselling related to JK’s
gender identity to cease. The father also sought to terminate JK’s legal representation by a particular
lawyer. In response, JK’s mother sought sole parental responsibility for JK, and JK sought to be joined
to the proceedings as a party. JK’s lawyer submitted that the father’s case was “in effect a claim against
JK, since [the father] is seeking to halt JK’s treatment”.146
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Skolrood J acceded to the application to join JK but found that JK should be represented by a
litigation guardian. His Honour said:
I agree … that this case is really about JK and his role in determining his own future. In my view, these
issues cannot be properly considered without JK’s direct participation, nor would it be fair to JK for the
court to attempt to do so.147

As the decision concerned only whether JK should be joined, the father’s substantive concerns – about
the dangers of the drug being currently administered to JK and that JK had not been properly diagnosed
– did not fall to be addressed.
JK’s case illustrates the potential complexities of decision-making in this area for children at the
very early stages of treatment for gender dysphoria. In several regards, it is quite different to an earlier
decision from Ontario, Halton Children’s Aid Society v GK.148 That case concerned a much younger
child, being only four years old. The child’s mother was found to be disregarding expert opinion that at
this age, her son was too young to be “socially transitioned” to be a girl, and it was not yet clear that any
desire to be a girl would persist.149 The judge found however that the children could continue to be cared
for by both parents under the supervision of the Children’s Aid Society.150
In terms of minors accessing treatment without the consent of either parent, there are reported cases
from several provinces of Canada indicating that a minor’s request for an abortion will be granted where
it is found to be in the child’s best interests despite parental opposition. In a case from Ontario, this was
achieved by taking the 14-year-old child into state care on a temporary basis.151 The court concluded that
the relevant statute required “the best interests of the child be given paramountcy over the valid, religious
concerns of her parents”.152 In a decision from Alberta, the parents challenged the finding that a 16-year
old had given informed consent to an abortion and sought an injunction to restrain the procedure.153
By reference to Gillick, the court found that the young person did have capacity to consent.154 The
differences between treatment for gender dysphoria and an abortion, however, are significant. An
abortion is a “one-off” procedure rather than an ongoing course of therapy. Moreover, as the discussion
of JK’s case above illustrates, children may be seeking treatment – at least suppression of puberty – prior
to the commencement of puberty.
The United States
In the United States, young people’s ability to access medical treatment in the face of parental opposition
is governed by State law. Such laws have developed particularly in response to minors seeking abortion.
This issue has given rise to what are referred to as “judicial bypass” procedures. While States may
legislate to require parental consent for a minor’s abortion when the minor is below a certain age, a
judicial bypass option must also be provided.155 This means that the statute must give the young person
the opportunity to seek the court’s permission to have an abortion instead.156 This came about through
constitutional challenges to State legislation purporting to compel minors to seek parental consent prior
to obtaining an abortion.157 However, in the context of treatment related to gender identity, Shield posits
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that “judges are no more likely to be knowledgeable about the needs of transgender adolescents than are
parents or the State”.158 Shield argues therefore that “judicial bypass” should be seen as a less preferable
option and that additional exceptions to seeking the consent of parents or guardians should instead
be sought. Specifically in relation to LGBTQ youth, Hoshall has also commented on the potential for
persons “in loco parentis” to consent to medical treatment for a child, but noted that this could be
difficult unless a court has already confirmed the person’s status.159
A child’s gender identity has been a subject of contention between his or her parents in at least
two United States cases. A decision of the Ohio Court of Appeals indicates some of the difficulties that
may arise for the court, the parties and particularly children, in cases where the child’s gender identity
becomes a site of contestation in custody proceedings.160 In the 2007 case of Smith v Smith, the mother
claimed that her natal son identified as female, a claim disputed by the child’s father. The appellate court
upheld the trial judge’s findings that the child did not in fact have gender dysphoria. The mother’s failure
to accept this lead ultimately to her losing custody of both her children. At the trial, four experts were
called, two who found that the child did have gender dysphoria and two who did not. However, the court
noted that none of the experts recommended any hormonal intervention, given that the child was aged
only nine years at the time. The mother’s apparent determination to enable such treatment to proceed
regardless clearly counted against her.
There is a brief reference to gender dysphoria in a much earlier decision from Texas. A 1998
decision of the Texas Court of Appeals involving a 10-year-old natal boy diagnosed with “gender identity
disorder” reports that the “recommended treatment was for [the child] to spend more time with his father,
and to lessen his dependence on his mother”.161 Another expert quoted in the case concluded that the
child’s mother “was unable to admit that [the child] had a problem, and that [he] needed to separate his
identity from his mother’s”.162 These findings contributed to the order that the two children should live
with their father.

V. CONCLUSION
The increasing numbers of young people seeking treatment for issues related to gender identity indicate
that increased knowledge in this area is important for both medical and legal professionals. There
is now a body of medical evidence that provides clear indications of the safety and appropriateness
of various pubertal suppression therapy, sex hormonal or surgical interventions. The suppression of
puberty, in particular, is safe with minimal side effects, as explored above. Suppression allows for the
commencement of sex hormone therapy to be delayed, providing greater certainty that the patient will
not “change their mind”.
As the court in Smith v Smith noted, there are “severe limitations in using the judicial system to resolve
complex and possibly controversial childrearing and childhood mental health issues”.163 Nevertheless,
it seems inevitable that disputes between children and their parents or guardians, and between parents
and guardians themselves, over questions of gender identity will continue to arise. Meanwhile, at least
in the common law legal systems discussed in this article, existing case law – dealing with such issues
as abortion, contraception or refusal of life-saving medical treatments – does not necessarily provide
useful guidance on how courts ought to approach treatment for gender dysphoria. The difficulties arising
through conflicting expert opinion on the subject of children’s gender identity are also apparent. While
presently rare, the increasing numbers of children and young people whose gender identity does not
conform to traditional roles will continue to test the limits of common law systems.
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